Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 17 | 2023 | 186 | 2.220 |
Why?
|
| Fluorescein Angiography | 12 | 2024 | 143 | 1.710 |
Why?
|
| Retinal Vessels | 10 | 2018 | 66 | 1.480 |
Why?
|
| Diabetic Retinopathy | 8 | 2018 | 179 | 1.260 |
Why?
|
| Macular Degeneration | 2 | 2023 | 159 | 1.200 |
Why?
|
| Retinopathy of Prematurity | 4 | 2023 | 140 | 1.180 |
Why?
|
| Choroid | 7 | 2016 | 62 | 1.070 |
Why?
|
| Retinal Neoplasms | 2 | 2024 | 26 | 1.050 |
Why?
|
| Retinal Vasculitis | 2 | 2024 | 10 | 1.040 |
Why?
|
| Macular Edema | 5 | 2018 | 43 | 1.030 |
Why?
|
| Retinal Diseases | 2 | 2023 | 87 | 0.910 |
Why?
|
| Choroidal Neovascularization | 4 | 2019 | 55 | 0.910 |
Why?
|
| Myopia, Degenerative | 1 | 2023 | 4 | 0.860 |
Why?
|
| Vitreous Detachment | 1 | 2023 | 9 | 0.850 |
Why?
|
| Vitreous Body | 1 | 2024 | 109 | 0.840 |
Why?
|
| Rituximab | 1 | 2024 | 164 | 0.840 |
Why?
|
| Myopia | 1 | 2023 | 47 | 0.810 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 181 | 0.760 |
Why?
|
| Laser Coagulation | 3 | 2018 | 57 | 0.690 |
Why?
|
| Telemedicine | 3 | 2023 | 792 | 0.630 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 325 | 0.570 |
Why?
|
| Fundus Oculi | 7 | 2024 | 61 | 0.530 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2016 | 38 | 0.500 |
Why?
|
| Retina | 3 | 2023 | 283 | 0.400 |
Why?
|
| Visual Acuity | 3 | 2024 | 326 | 0.350 |
Why?
|
| Intravitreal Injections | 3 | 2024 | 56 | 0.280 |
Why?
|
| Microcirculation | 2 | 2017 | 145 | 0.260 |
Why?
|
| Geographic Atrophy | 2 | 2016 | 68 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 528 | 0.240 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 3084 | 0.230 |
Why?
|
| Capillaries | 4 | 2018 | 103 | 0.220 |
Why?
|
| Traction | 1 | 2023 | 19 | 0.210 |
Why?
|
| Ophthalmology | 1 | 2023 | 82 | 0.190 |
Why?
|
| Macula Lutea | 2 | 2018 | 21 | 0.180 |
Why?
|
| Humans | 24 | 2024 | 129687 | 0.180 |
Why?
|
| Fovea Centralis | 2 | 2019 | 11 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 218 | 0.170 |
Why?
|
| Retinoblastoma | 1 | 2021 | 31 | 0.170 |
Why?
|
| Photography | 1 | 2021 | 93 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 86 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 739 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2020 | 163 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2023 | 14525 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2023 | 5759 | 0.150 |
Why?
|
| Retinal Neovascularization | 1 | 2018 | 25 | 0.150 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 5083 | 0.150 |
Why?
|
| Regional Blood Flow | 2 | 2017 | 463 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 4892 | 0.150 |
Why?
|
| Retinitis | 1 | 2017 | 20 | 0.140 |
Why?
|
| Retinal Artery Occlusion | 1 | 2017 | 8 | 0.140 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2017 | 30 | 0.140 |
Why?
|
| Aneurysm | 1 | 2017 | 31 | 0.140 |
Why?
|
| Visual Fields | 1 | 2017 | 87 | 0.140 |
Why?
|
| Optic Disk | 1 | 2017 | 40 | 0.140 |
Why?
|
| Optic Disk Drusen | 1 | 2016 | 6 | 0.130 |
Why?
|
| Choroid Diseases | 1 | 2016 | 10 | 0.130 |
Why?
|
| Ranibizumab | 1 | 2016 | 20 | 0.130 |
Why?
|
| Retinal Drusen | 1 | 2016 | 31 | 0.130 |
Why?
|
| Internet | 1 | 2020 | 619 | 0.130 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2016 | 70 | 0.120 |
Why?
|
| Bevacizumab | 1 | 2016 | 128 | 0.120 |
Why?
|
| Ischemia | 1 | 2018 | 405 | 0.120 |
Why?
|
| Wet Macular Degeneration | 1 | 2016 | 45 | 0.120 |
Why?
|
| Gestational Age | 3 | 2023 | 874 | 0.110 |
Why?
|
| Male | 15 | 2023 | 63691 | 0.100 |
Why?
|
| Aged | 8 | 2019 | 22101 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1005 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2022 | 5434 | 0.090 |
Why?
|
| Female | 14 | 2023 | 68751 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2023 | 7145 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 7064 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 6545 | 0.080 |
Why?
|
| Middle Aged | 9 | 2019 | 31165 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 1844 | 0.070 |
Why?
|
| Artifacts | 2 | 2016 | 126 | 0.060 |
Why?
|
| Computed Tomography Angiography | 2 | 2016 | 115 | 0.060 |
Why?
|
| Ophthalmoscopy | 1 | 2023 | 35 | 0.050 |
Why?
|
| Smartphone | 1 | 2023 | 87 | 0.050 |
Why?
|
| Nepal | 1 | 2021 | 22 | 0.050 |
Why?
|
| Mongolia | 1 | 2020 | 6 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 109 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 176 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 306 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 245 | 0.040 |
Why?
|
| North America | 1 | 2021 | 292 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 503 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2023 | 541 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 284 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 314 | 0.040 |
Why?
|
| Birth Weight | 1 | 2021 | 505 | 0.030 |
Why?
|
| Doppler Effect | 1 | 2017 | 3 | 0.030 |
Why?
|
| Vitrectomy | 1 | 2017 | 66 | 0.030 |
Why?
|
| Microaneurysm | 1 | 2016 | 1 | 0.030 |
Why?
|
| Adult | 4 | 2023 | 35607 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 110 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 406 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 2644 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 903 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Infant | 1 | 2023 | 8987 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1616 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3381 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2739 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 9787 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 2443 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 10221 | 0.010 |
Why?
|